Register
Login:
Share:
Email Facebook Twitter


#AST: Board changes and new strategy for Ascent as Hutchinson looks at new projects
EXCLUSIVE: Petro Matad announce fully funded 4 well Mongolia campaign


Midatech Pharma Share Chat (MTPH)



Share Price: 5.375Bid: 5.25Ask: 5.50Change: 0.00 (0.00%)No Movement on Midatech Pharma
Spread: 0.25Spread as %: 4.76%Open: 5.125High: 5.375Low: 5.125Yesterday’s Close: 5.375


Share Discussion for Midatech Pharma


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

 
Profit_profit
Posts: 1,230
Premium Chat Member
Opinion:No Opinion
Price:5.375
RE: Massive news!!!
Sun 22:15
I think lot's of people not aware of the Company's progress. I've posted links. All welcome to read and analyze.
Profit_profit
Posts: 1,230
Premium Chat Member
Opinion:No Opinion
Price:5.375
RE: Massive news!!!
Sun 22:14
Hope we get a good RNS this week.
Jarv55
Posts: 8,587
Opinion:No Opinion
Price:5.375
RE: Massive news!!!
Sun 19:16
So early Q1 fda approval and this think any US shorts are going to have to close soon.
In addition to the above priority programs, Midatech's gold nanoparticle technology MidaCore continues to be evaluated via several research collaborations, including clinically as a drug or peptide delivery platform for autoimmune disease as a vaccine for diabetes with the Phase I study due to read out early 2019, as well as preclinically for solid tumour cancer vaccines and treatments, viral vaccines, and psoriasis treatment.
Profit_profit
Posts: 1,230
Premium Chat Member
Opinion:No Opinion
Price:5.375
RE: Massive news!!!
Sun 18:53
Highlights

· Company in advanced discussions with a new strategic investor regarding a potential substantial investment in the Company and licence to develop the Group's products in Asia
Profit_profit
Posts: 1,230
Premium Chat Member
Opinion:No Opinion
Price:5.375
RE: Mtph
Sat 18:31
Big companies are starting to take note of the delivery platform, too, with an unnamed "leading global pharma corporation" recently agreeing a deal to trial the technology.
Profit_profit
Posts: 1,230
Premium Chat Member
Opinion:No Opinion
Price:5.375
RE: Mtph
Sat 18:30
Sustained release system
Midatech’s Q-Sphera technology works to deliver a drug to the right place at the right time.

It is a sustained release platform and the company has adopted 3D and inkjet printing techniques to create particles that dissolve in a certain way over a certain time-scale.
Profit_profit
Posts: 1,230
Premium Chat Member
Opinion:No Opinion
Price:5.375
RE: Mtph
Sat 18:27
After five years of development, we are delighted to have achieved positive first-in-human data,” said chief executive Craig Cook.

“First, for the MTD201 programme, whilst one objective of the study was to determine whether MTD201 was bioequivalent to Sandostatin LAR with a potentially shorter route to market, this data suggests that we have a better product with an improved clinical profile.

“Combined with the other advantages around smaller needle size, simpler and more reliable reconstitution and injection, this could lead to a more valuable product either to develop internally or license to pharmaceutical partners.
Profit_profit
Posts: 1,230
Premium Chat Member
Opinion:No Opinion
Price:5.375
RE: Mtph
Sat 18:26
Several advantages
Like SLAR, MTD201 was safe and effective, but among the key advantages is that it requires a smaller needle which blocks less frequently.

The reconstitution process – adding a diluent to the drug – was found to be simpler with MTD201, leading to fewer reconstitution errors and less wastage.

Perhaps most importantly though, the results provide a successful clinical 'proof of concept' for Midatech's Q-Sphera sustained release technology, which it is using in some of the other drugs it is testing.

Ahead of a follow-on trial, the company will speak to regulators to get their opinion on whether to pursue MTD201 as an equivalent to, or improved version of Novartis’ SLAR.
Profit_profit
Posts: 1,230
Premium Chat Member
Opinion:No Opinion
Price:5.375
RE: Mtph
Sat 18:25
The first-in-human data for Midatech Pharma PLC’s (LON:MTPH) MTD201 drug has suggested it is better than a rival product made by Swiss pharma giant Novartis.

MTD201 is being developed as a treatment for a hormonal disorder called acromegaly, as well as for carcinoid cancer.

Novartis has already cornered a large slice of the market with its Sandostatin LAR drug, but the interim data has shown MTD201 to be, at worst, a good alternative or, at best, a “differentiated improved product”.
Profit_profit
Posts: 1,230
Premium Chat Member
Opinion:No Opinion
Price:5.375
Mtph
Sat 18:23
Data from Midatech's MTD201 drug has validated the company's Q-Sphera sustained release technology, and other, bigger players are starting to sit up and take note
Jarv55
Posts: 8,587
Opinion:No Opinion
Price:5.375
Mtph
Fri 14:52
Nasdaq up 10%
Jarv55
Posts: 8,587
Opinion:No Opinion
Price:5.125
RE: Adding a few more today
Fri 12:57
Chart has tight bollingers, and bullish divergence and a double bottom so news would be welcomed.

https://invst.ly/9tje-
Jarv55
Posts: 8,587
Opinion:No Opinion
Price:5.125
RE: Adding a few more today
Fri 12:37
Well George don't want to jinx it but looks like the selling has dried up. Just bored pi's selling now.
George-Inn
Posts: 154
Opinion:No Opinion
Price:5.125
Adding a few more today
Fri 12:11
The 5p price is just too good to leave on the table. Besides I believe that news is forthcoming next week or two regarding updates to funding, partnering and possibly FDA direction. It's my belief that 5p will be short lived and I want to load more while I can. All just my personal opinion, good luck to all. In a couple of more hours it will be time to head down and across the street to a couple of pints and F&C's. Hope we get some news....
Jarv55
Posts: 8,587
Opinion:No Opinion
Price:5.25
Mpth
Thu 14:21
Nice price for the 6k buyer there
Jarv55
Posts: 8,587
Opinion:No Opinion
Price:5.625
RE: RNS Legal & General
Wed 20:28
If they post anything interesting I will post it here.
NicetoMichu
Posts: 170
Opinion:No Opinion
Price:5.625
RE: RNS Legal & General
Wed 18:54
thanks but I'm sad enough being on the UK BB and so will leave the US one in your capable hands.. please update here off the back as you see fit.. PS; good updating by you here generally, thanks.
NicetoMichu
Posts: 170
Opinion:No Opinion
Price:5.625
RE: RNS Legal & General
Wed 18:51
indeed Jarv55.. City Financial selling down too.. 'not ideal' as they say..
Jarv55
Posts: 8,587
Opinion:No Opinion
Price:5.625
RE: RNS Legal & General
Wed 18:47
Just to let you know there is an American bb https://stocktwits.com/symbol/MTP
Jarv55
Posts: 8,587
Opinion:No Opinion
Price:5.625
RE: RNS Legal & General
Wed 18:46
Fair enough NTM
NicetoMichu
Posts: 170
Opinion:No Opinion
Price:5.625
RE: RNS Legal & General
Wed 18:40
No Jarv55.. and I have no interest in doing so either.. the s/p performance here speaks volumes.. but hopefully they can save the day in the end..

generally, if I lose all my bet here so be it as I'll have contributed to medical science potential advancement at least .. if I do ok/well/very well in the end so be it too and I'll make a donation to cancer research off the back..

...but either way i'll see this as a bad bet by me ..
Jarv55
Posts: 8,587
Opinion:No Opinion
Price:5.625
Mtph
Wed 18:21
Jarv55
Posts: 8,587
Opinion:No Opinion
Price:5.875
RE: RNS Legal & General
Tue 23:37
NicetoMichu have you ever had communications with the bod?




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk









Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.